Accueil/Actions/RXRX

RXRX

USD

Recursion Pharmaceuticals Inc. Class A Common Stock

$5.000-0.200 (-3.846%)

Prix en Temps Réel

Healthcare

Biotechnologie

États-Unis

Graphique des Prix

Loading Chart...

Métriques Clés

Métriques de Marché

Fondamentaux de l'Entreprise

Statistiques de Trading

Métriques de Marché

Ouverture

$5.200

Haut

$5.320

Bas

$4.970

Volume

57.15M

Fondamentaux de l'Entreprise

Capitalisation Boursière

2.2B

Industrie

Biotechnologie

Pays

United States

Statistiques de Trading

Volume Moyen

39.05M

Bourse

NMS

Devise

USD

Intervalle sur 52 Semaines

Bas $3.79Actuel $5.000Haut $12.36

Actualités Connexes

4 nov. 2025 · 13:00

GlobeNewswire

Recursion to Participate in Upcoming Investor Conferences

Salt Lake City, Nov. 04, 2025 (GLOBE NEWSWIRE) -- Recursion (NASDAQ:RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, announced today its participation in the following

Recursion to Participate in Upcoming Investor Conferences

28 oct. 2025 · 12:00

GlobeNewswire

Recursion to Report Third Quarter 2025 Business Updates and Financial Results on November 5th

Salt Lake City, UT, Oct. 28, 2025 (GLOBE NEWSWIRE) -- Recursion (NASDAQ:RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, announced today it will provide business updates and

Recursion to Report Third Quarter 2025 Business Updates and Financial Results on November 5th

27 oct. 2025 · 11:23

Reuters

Buybacks take backseat as AI drives record US capex spending

Investors are increasingly favoring U.S. companies that channel capital toward AI innovation over those offering traditional shareholder payouts such as dividends and buybacks, even as the debate over soaring valuations and an AI bubble rages on.